Lipoprotein(a) oxidation and autoantibodies: A new path in atherothrombosis

Lupus

Volumn 9, Issue 3, 2000, Pages 206-209

  Romero, F I ^a   Khamashta, M A ^a   Hughes, G R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Malondialdehyde modified Lp(a); Oxidized LDL; Oxidized Lp(a); Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTERY WALL; ATHEROSCLEROSIS; AUTOIMMUNITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034032719     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828253     Document Type: Short Survey

References (39)

1. Gaubatz JW, Heldeman C, Gotto AMJ et al. Isolation and characterization of the two major apoproteins in human lipoprotein(a). J Biol Chem 1983; 258: 4582-4589.
2. Uterman G. The mysteries of lipoprotein(a). Science 1989; 246: 904-910.
3. Berg K. A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand 1963; 59: 369-382.
4. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-β1-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-235.
5. Dahlen G, Guyton JR, Attar M et al. Association of plasma levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-765.
6. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-1715.
7. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic cerebrovascular disease in young adults. Stroke 1994; 25: 74-78.
8. Rath M, Niendorf A, Reblin T et al. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-592.
9. Cushing GL, Gaubatz JW, Nava ML et al. Quantitation and localization of apolipoproteins (a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9: 593-603.
10. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32: 317-327.
11. Scanu AM. Lipoprotein (a), a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988; 112: 1045-1047.
12. Scanu AM. Lipoprotein(a): a genetically determined cardiovascular pathogen in search of a function. J Lab Clin Lab 1990; 116: 142-146.
13. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
14. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-2496.
15. Ylä-Herttuala S, Palinsky W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-1095.
16. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1991; 1081: 65-74.
17. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein (a) and the effect of β-carotene. Metabolism 1992; 11: 1215-1224.
18. Kleinveld HA, Duif PF, van Rijn IIJ. Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions. Biochim Biophys Acta 1996; 1303: 15-21.
19. Naruszewicz M, Selinger E, Dufour R, Davignon J. Probucol protects lipoprotein (a) against oxidative modification. Metabolism 1992; 11: 1225-1228.
20. Ragab MS, Selvaraj P, Sgoutas D. Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. Atherosclerosis 1996; 123: 103-113.
21. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein (a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 6: 4143-4151.
22. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation 1995; 92: 1582-1589.
23. Hoff HF, O'Neil J, Yashiro A. Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res 1993; 34: 789-798.
24. Naruszewicz M, Giroux LM, Davignon J. Oxidative modification of Lp(a) causes changes in the structure and biological properties of Lp(a). Chem Phys Lipids 1994; 167: 67-68.
25. Ren S, Man RYK, Angel A, Shen GX. Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis 1997; 128: 1-10.
26. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
27. Palinski W, Ylä-Herttuala S, Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Atherosclerosis 1990; 10: 325-335.
28. Vaarala O. Atherosclerosis in SLE and Hughes syndrome. Lupus 1997; 6: 489-490 (editorial).
29. Vaarala O, Alfthan G, Jauhiainen M et al. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.
30. Hörkko S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815-825.
31. Iuliano L, Pratico D, Ferro D et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997; 90: 3931-3935.
32. Romero FI, Amengual O, Atsumi T et al. Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998; 37: 883-888.
33. Amengual O, Atsumi T, Khamashta MA et al. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997; 36: 964-968.
34. Yamazaki M, Asakura H, Jokaji H et al. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid syndrome. Thromb Haemost 1994; 71: 424-427.
35. Atsumi T, Khamashta MA, Andújar C et al. Elevated plasma lipoprotein (a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998; 25: 69-73.
36. Borba EF, Santos RD, Bonfa E et al. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-223.
37. Romero FI, Atsumi T, Tinahones FJ et al. Autoantibodies against malondialdehyde-modified lipoproteia(a) in the antiphospholipid syndrome. Arthritis Rheum 1999; 42 in press. (Dec 1999)
38. Romero FI, Khamashta MA, Atsumi T et al. Autoantibodies against oxidized lipoprotein(a) in systemic lupus erythematosus (SLE). Arthritis Rheum 1999; 42(Suppl): SI47.
39. Matsuura E, Kobayashi K, Yasuda T, Koike T. Antiphospholipid antibodies and atherosclerosis. Lupus 1998; 7: S135-S139.